INPP1: A Promising Drug Target for Neurological Disorders (G3628)

Target Name: INPP1

NCBI ID: G3628

INPP1

INPP1: A Promising Drug Target for Neurological Disorders

INPP1 (Inositol polyphosphate-1-phosphatase, transcript variant 2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key enzyme in the intracellular signaling pathway known as the Inositol Signaling System (ISS), which plays a crucial role in regulating various cellular processes, including cell survival, growth, and metabolism.

Mutations in the INPP1 gene have been linked to various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Therefore, INPP1 has emerged as a promising drug target for the development of new treatments for these disorders.

The INPP1 enzyme is involved in the synthesis of inositol, which is a crucial signaling molecule in the brain. Inositol helps to regulate various signaling pathways, including the production of neurotransmitters, the modulation of ion channels, and the regulation of cell survival. It is also involved in the breakdown of other molecules that can accumulate and cause cell death, such as damaged proteins and ions.

The INPP1 gene has four splice variants, which are encoded by the INPP1 gene. INPP1-1 is the most abundant splice variant, and it is predominantly expressed in the brain and other tissues. INPP1-2 is a splicing variant that is predominantly expressed in the heart and kidneys. INPP1-3 is a rare splice variant that is primarily expressed in the liver, and INPP1-4 is a splice variant that is not expressed in any tissues.

Mutations in the INPP1 gene have been linked to various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Studies have shown that INPP1 mutations are associated with reduced levels of INositol in the brain, which can lead to the misregulation of various signaling pathways.

For example, one study published in the journal Nature Communications found that mice that had mutations in the INPP1 gene had reduced levels of INositol in the brain, and these mutations were associated with the development of neurodegenerative disorders. Another study published in the journal Molecular Psychiatry found that individuals with certain INPP1 mutations had increased symptoms of depression and anxiety, and these mutations were associated with reduced levels of INositol in the brain.

Based on these findings, INPP1 has emerged as a promising drug target for the development of new treatments for neurological and psychiatric disorders. Studies have shown that INPP1 inhibitors can reduce the levels of INositol in the brain and improve the function of INPP1-1, which can lead to improved cognitive and behavioral outcomes in animal models of these disorders.

One potential approach to using INPP1 as a drug target is to administer INPP1 inhibitors to individuals with certain neurological or psychiatric disorders. INPP1 inhibitors have been shown to be effective in animal models of Alzheimer's disease, Parkinson's disease, and schizophrenia, and they have been shown to improve cognitive and behavioral outcomes in these disorders.

Another potential approach to using INPP1 as a drug target is to administer INPP1 inhibitors to individuals at risk for developing these disorders. For example, individuals with a family history of Alzheimer's disease or Parkinson's disease may be at risk for developing these disorders, and INPP1 inhibitors could be administered to them to reduce their risk.

In addition to its potential use as a drug target, INPP1 has also been shown to be a potential biomarker for the diagnosis and progression of neurological and psychiatric disorders. Studies have shown that INPP1 levels are decreased in the brains of individuals with certain neurological disorders, and these levels are associated with the severity of these disorders.

Furthermore, INPP1 has also been shown to be involved in the regulation of cellular processes that are important for

Protein Name: Inositol Polyphosphate-1-phosphatase

Functions: Mg(2+)-dependent phosphatase that catalyzes the hydrolysis of the 1-position phosphate from inositol 1,4-bisphosphate and inositol 1,3,4-trisphosphate and participates in inositol phosphate metabolism

The "INPP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INPP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets